Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Yuviwel (navepegritide) Coverage Update…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.746

    Navepegritide (Yuviwel) — Coverage Criteria for Achondroplasia

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.746 alerts

    Get alerted when Policy CP.PHAR.746 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for navepegritide (Yuviwel) for pediatric achondroplasia across applicable QualChoice lines of business (Commercial, ICHRA/HIM, Medicaid). Affects providers requesting coverage for initiation and continuation of therapy.

    Policy Summary
    PayerQualChoice
    PolicyNavepegritide (Yuviwel) — Coverage Criteria for Achondroplasia
    Policy CodePolicy CP.PHAR.746
    Change TypeCriteria revised (dosing/quantity) + concurrency prohibition added
    Effective DateFeb 27, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation (diagnosis with FGFR3 genetic confirmation, radiographs showing open epiphyses, baseline 6‑month growth velocity, and current weight) to request initiation or continuation of Yuviwel.
    SourceLink
    POLICY UPDATE CHANGES

    Criteria updated per prescribing information to include weight-based dosing and quantity limits.

    Added requirement that Yuviwel is not prescribed concurrently with Voxzogo and any human growth hormone products for continued therapy.

    ICHRA (health insurance marketplace/ICHRA) line of business was added.

    2 to <12 yrsApproved pediatric age range
    6 monthsApproval period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 or 2/week
    Vial limits
    1.3, 2.8, 5.5 mgVial sizes

    Coverage Criteria for Yuviwel (navepegritide)

    Non‑FDA indications not specifically addressed in this policy are not authorized for coverage unless the provider submits sufficient supporting evidence per the applicable off‑label use policies for the member's line of business (see referenced off‑label policies). Requests for uses outside the FDA‑approved indication should be routed through the insurer’s off‑label/formulary review process prior to coverage consideration.

    Requests that fail to meet the documented diagnostic, age, radiographic, dosing, or documentation requirements are considered not medically necessary and may be denied. Examples include missing genetic confirmation of an FGFR3 mutation, absence of radiographic evidence of open epiphyses, lack of baseline annualized growth velocity or current weight documentation, or doses exceeding the weight‑based weekly dosing table and vial limits. Therapy that is prescribed concurrently with disallowed agents (any human growth hormone product or Voxzogo) will not meet coverage criteria and may result in denial.

    Initial Therapy Criteria and Approval

    Continued Therapy Criteria and Renewal

    Coding, Age, and Dosing Summary

    HCPCS Codes (informational)HCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    Age
    Eligible age range>= 2 and < 12 years
    Approval duration6 months (per initial/continued therapy criteria)
    FDA indication contextIndicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
    Weight-based dosing ranges
    8.0–9.9 kg0.88 mg per week
    10.0–13.4 kg1.2 mg per week
    13.5–17.5 kg1.6 mg per week
    17.6–23.0 kg2.1 mg per week
    23.1–30.5 kg2.8 mg per week
    30.6–41.2 kg3.6 mg per week
    41.3–55.9 kg5.0 mg per week
    56.0–73.5 kg6.6 mg per week
    73.6–90.0 kg

    Quantity and Vial Limits

    Yuviwel (navepegritide) — vial limits & product availability
    Standard vial limit1 vial per week
    Higher vial limit for weight 56–90 kg2 vials per week for patients weighing 56–90 kg
    Available vial sizesSingle-dose lyophilized vials: 1.3 mg, 2.8 mg, 5.5 mg

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required — 6‑month approvals

    Yuviwel (navepegritide) requires prior authorization. Approvals are issued only when the request meets the applicable Initial or Continued Therapy criteria in this policy; approval duration is 6 months.

    Step Therapy

    Off‑label and formulary routing — follow line‑of‑business policies

    If the requested use, diagnosis, age, or dosing is not listed in this policy or the drug recently had a label change, route the request per the applicable formulary/non‑formulary or off‑label use policy for the member's line of business before coverage consideration.

    • Refer to formulary/no‑coverage or non‑formulary policies when the drug recently had a label change (see list in policy).
    • If the requested use is not listed in section III and criterion above does not apply, follow the off‑label use policy for the relevant line of business (CP.CPA.09, HIM.PA.154, or CP.PMN.53).

    Definitions and Diagnostic Criteria

    Open epiphyses
    DefinitionRadiographic evidence of open epiphyses (growth plates) is required at initiation of therapy
    Continued therapy requirementRadiographic evidence within the last 4 months indicating continued open epiphyses is required for continuation
    Documentation sourceProvider must submit radiographs as supporting documentation to demonstrate open growth plates
    Achondroplasia (FGFR3 mutation)
    Required testGenetic testing confirming a mutation in the FGFR3 gene is required to establish diagnosis of achondroplasia
    Diagnostic contextDiagnosis of achondroplasia with FGFR3 mutation is a criterion for initial approval

    Step Therapy and Formulary Routing

    StepRule / Action
    1If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy (e.g., new indication, age expansion, new dosing), route the request to the appropriate formulary or non‑coverage policy for the member's line of business: for formulary drugs use the no coverage criteria policies (CP.CPA.190 — commercial; HIM.PA.33 — ICHRA/marketplace; CP.PMN.255 — Medicaid); for non‑formulary drugs use the non‑formulary policies (CP.CPA.190 — commercial; HIM.PA.103 — ICHRA/marketplace; CP.PMN.16 — Medicaid).
    2If the requested use (diagnosis, age, dosing regimen) is not listed in Section III and criterion 1 does not apply, refer the request to the off‑label use policy for the member's line of business (CP.CPA.09 — commercial; HIM.PA.154 — ICHRA/marketplace; CP.PMN.53 — Medicaid) before considering coverage.

    Site of Care

    Note

    No site‑of‑care restriction stated

    The policy does not impose a site‑of‑care restriction; administration setting is not limited by this policy.

    Background

    Navepegritide (brand name Yuviwel) is a C‑type natriuretic peptide (CNP) prodrug indicated to increase linear growth in pediatric patients with achondroplasia. The policy supports its use in children with genetically confirmed achondroplasia (FGFR3 mutation) who have open epiphyses. Initiation and continued therapy require documentation of age, radiographic open growth plates, baseline and on‑therapy annualized growth velocity, and current weight, with dosing constrained to the weight‑based weekly dosing table and the policy’s vial limits.

    Policy Summary
    PayerQualChoice
    PolicyNavepegritide (Yuviwel) — Coverage Criteria for Achondroplasia
    Policy CodePolicy CP.PHAR.746
    Change TypeCriteria revised (dosing/quantity) + concurrency prohibition added
    Effective DateFeb 27, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation (diagnosis with FGFR3 genetic confirmation, radiographs showing open epiphyses, baseline 6‑month growth velocity, and current weight) to request initiation or continuation of Yuviwel.
    SourceLink
    On This Page
    Coverage Criteria for Yuviwel (navepegritide)Initial Therapy Criteria and ApprovalContinued Therapy Criteria and RenewalCoding, Age, and Dosing SummaryQuantity and Vial LimitsProvider Actions, Prior Authorization, and DocumentationDefinitions and Diagnostic CriteriaStep Therapy and Formulary RoutingSite of CareBackground
    8.8 mg per week
    Documentation Required

    Required documentation to support approval

    Submit supporting clinical documentation with the prior authorization request to show the member meets all criteria. Required items include office chart notes and objective data described in the criteria.

    • Office chart notes or clinical progress notes documenting diagnosis and prescribing clinician (pediatric endocrinologist involvement).
    • Radiographs showing open epiphyses at initiation and radiographs within 4 months for continuation.
    • Genetic testing confirming FGFR3 mutation.
    • Baseline annualized growth velocity calculated from standing height over the 6 months prior to request.
    • Documentation of current weight in kilograms.
    Denial Risk

    Documentation & concurrent therapy exclusions — denial risks

    Requests lacking the required documentation or proposing concurrent use with disallowed agents will be denied. Denial triggers include missing confirmation of diagnosis/FGFR3 mutation, absent radiographs showing open epiphyses, missing baseline growth velocity or current weight, or concurrent prescription of any human growth hormone product or Voxzogo.

    • Concurrent therapy exclusion: Yuviwel must not be prescribed concurrently with any human growth hormone products (e.g., Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zomacton).
    • Concurrent therapy exclusion: Yuviwel must not be prescribed concurrently with Voxzogo.
    • Missing required documentation as listed (diagnosis confirmation, radiographs, baseline growth velocity, current weight) may result in denial.
    Policy implicationProvider must submit genetic testing results as part of required documentation for prior authorization